Case 9: Pricing the EpiPen: This is Going to Sting

What should Heather Bresch do? Why? What risks do you see with this plan of action?

Does the variation in prices across countries seem reasonable? What happens if Mylan were forced to make its price more consistent?

What changes, if any, would you make to Mylan's pricing policy? Is there a better way to structure the discounts?

What is the biggest risk that Bresch faces?